These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23418703)

  • 1. Androgen deprivation therapy: further confirmation of known harms.
    Beebe-Dimmer JL; Freedland SJ
    BJU Int; 2013 May; 111(5):690-1. PubMed ID: 23418703
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
    Griebling TL
    J Urol; 2014 Feb; 191(2):388. PubMed ID: 24411874
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidemiology of male osteoporosis and prostate cancer.
    Gilbert SM; McKiernan JM
    Curr Opin Urol; 2005 Jan; 15(1):23-7. PubMed ID: 15586025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies report risks associated with androgen deprivation therapy.
    Printz C
    Cancer; 2011 Apr; 117(8):1559. PubMed ID: 21472702
    [No Abstract]   [Full Text] [Related]  

  • 7. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
    Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
    J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis and anti-androgenic therapy in case of prostate cancer].
    Uebelhart B; Rizzoli R
    Rev Med Suisse; 2005 Oct; 1(35):2261-2, 2264-5. PubMed ID: 16268448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of fracture after androgen deprivation for prostate cancer.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991
    [No Abstract]   [Full Text] [Related]  

  • 14. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
    Aragon-Ching JB
    J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bone loss in men under androgen-deprivation therapy for prostate cancer].
    Ishizaka K; Machida T; Yoshida K
    Nihon Rinsho; 2005 Apr; 63(4):721-6. PubMed ID: 15828242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoporosis fracture in a male patient secondary to hypogonadism due to androgen deprivation treatment for prostate cancer].
    Verdú Solans J; Roig Grau I; Almirall Banqué C
    Semergen; 2014; 40(4):e73-6. PubMed ID: 23768568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate prescriptions in men with androgen deprivation therapy use.
    Gulamhusein H; Yun L; Cheung AM; Sutradhar R; Paszat L; Warde P; Alibhai SM
    JAMA; 2014 Dec; 312(21):2285-6. PubMed ID: 25462000
    [No Abstract]   [Full Text] [Related]  

  • 19. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing the side effects of androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):97-8. PubMed ID: 16499136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.